# AK129 Combination Therapy for Advanced Solid Tumors

> **NCT06943820** · PHASE1,PHASE2 · RECRUITING · sponsor: **Akeso** · enrollment: 230 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage IIIB/IV
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Colorectal Adenocarcinoma
- Advanced Solid Tumors

## Interventions

- **DRUG:** AK129(dose 1)
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** AK129(dose 2)
- **DRUG:** Docetaxel
- **DRUG:** Cis-platinum
- **DRUG:** 5-FU (5-fluorouracil)
- **DRUG:** Cetuximab
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Chemotherapy
- **DRUG:** AK129(RP2D)
- **DRUG:** Penpulimab

## Key facts

- **NCT ID:** NCT06943820
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-21
- **Primary completion:** 2026-12
- **Final completion:** 2028-05
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06943820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06943820, "AK129 Combination Therapy for Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06943820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*